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Abstract
α2-adrenoceptors are widely distributed throughout the central nervous system (CNS) and the 
systemic administration of α2-agonists such as dexmedetomidine produces clinically useful, 
centrally-mediated sedation and analgesia; however, these same actions also limit the utility of 
these agents (ie unwanted sedative actions). Despite a wealth of data on cellular and synaptic 
actions of α2-agonists in vitro, it is not known which neuronal circuits are modulated in vivo to 
produce the analgesic effect. To address this issue, we made in vivo recordings of membrane 
currents and synaptic activities in superficial spinal dorsal horn neurons and examined their 
responses to systemic dexmedetomidine. We found that dexmedetomidine at doses that produce 
analgesia (<10 μg/kg) enhanced inhibitory postsynaptic transmission within the superficial dorsal 
horn without altering excitatory synaptic transmission or evoking direct postsynaptic membrane 
currents. In contrast, higher doses of dexmedetomidine (>10 μg/kg) induced outward currents by a 
direct postsynaptic action. The dexmedetomidine-mediated inhibitory postsynaptic current (IPSC) 
facilitation was not mimicked by spinal application of dexmedetomidine and was absent in 
spinalized rats, suggesting it acts at a supraspinal site. Further it was inhibited by spinal 
application of the α1-antagonist prazosin. In the brain stem, low doses of systemic 
dexmedetomidine produced an excitation of locus coeruleus neurons. These results suggest that 
systemic α2-adrenoceptor stimulation may facilitate inhibitory synaptic responses in the 
superficial dorsal horn to produce analgesia mediated by activation of the pontospinal 
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noradrenergic inhibitory system. This novel mechanism may provide new targets for intervention 
perhaps allowing analgesic actions to be dissociated from excessive sedation.
1. Introduction
Clinically α2-adrenoceptor agonists such as dexmedetomidine are widely used as sedative 
agents, as adjuncts to anesthesia and have been noted to produce analgesic effects [9; 13; 
38]. Dexmedetomidine is a potent analgesic but the accompanying sedation (and 
hypotension) produced by systemic administration has limited the widespread deployment 
of α2-agonists as analgesics and prompted investigations to separate these effects. It has 
been suggested that the sedative action of dexmedetomidine is primarily mediated by 
inhibition of locus coeruleus (LC) neurons, which has an important role in attention and 
arousal [2; 4; 12; 15]. Whereas there is evidence suggesting that the spinal cord is the 
principal site for its analgesic action [35; 61], and previous behavioral studies have shown 
that intrathecal or epidural dexmedetomidine is antinociceptive [3; 18]. However, there is 
conflicting evidence suggesting that after systemic administration it may act to produce 
analgesia via an action at the LC [26].
In addition to the LC and spinal cord, α2-adrenoceptors are widely distributed throughout 
the central nervous system (CNS) and mediate responses to the release of endogenous 
central catecholamines [24; 43]. Activation of postsynaptic α2-adrenoceptors produces 
hyperpolarization by the activation of G protein-coupled inwardly-rectifying potassium 
channels via Gi/o-proteins. Presynaptic α2-adrenoceptors reduce neurotransmitter release by 
inhibiting calcium influx (see review [52]). In the noradrenergic neurons of the LC, α2-
adrenoceptors act as autoreceptors to reduce local noradrenaline release [33] and also induce 
postsynaptic hyperpolarization [2; 12; 15].
Within spinal nociceptive circuits, the substantia gelatinosa (SG, lamina II) neurons in the 
superficial dorsal horn play an important role in the transmission and modulation of 
nociceptive information [11; 20]. The SG receives nociceptive information via glutamatergic 
synapses from peripheral Aδ- and C- afferent fibers [22; 42; 44; 47; 63; 66]. SG neurons 
also receive abundant inhibitory synaptic inputs from spinal GABAergic and glycinergic 
interneurons [7; 41; 48; 68] and receive a dense innervation from a descending inhibitory 
system including noradrenergic fibers from the LC [8; 30; 50; 55]. A number of in vitro 
studies have shown spinal α2-agonists to produce both post-synaptic hyperpolarization [49] 
and presynaptic inhibition of excitatory transmission [37]. A recent electrophysiological 
study has specifically shown dexmedetomidine to have a direct inhibitory action on SG 
neurons in vitro [31]. It is likely that these mechanisms mediate the analgesic effects of 
spinally administered α2-agonists, but it is not known whether the systemic administration 
of dexmedetomidine acts to modulate spinal nociceptive processing in a similar manner.
We have developed an in vivo patch-clamp recording technique from SG neurons in 
allowing the detailed analysis of synaptic responses and changes in intrinsic membrane 
properties [19; 22]. We used this approach to test the hypothesis that systemic 
dexmedetomidine, at analgesic doses, acts to inhibit SG neurons in vivo by one of the 
previously reported mechanisms [37; 49]. We found that low-dose dexmedetomidine (at 
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doses below that shown to have sedative actions) dramatically enhanced spinal inhibitory 
transmission (without effects on excitatory transmission or intrinsic membrane 
conductances) by activation of the pontospinal descending noradrenergic circuit.
2. Materials and methods
2.1 Animals
Ninety male Sprague-Dawley rats aged 5-9 weeks, weighing 150-350 g were used in this 
study. The animals were purchased from Japan SLC (Hamamatsu, Japan) and housed in a 
temperature-controlled room (21 ± 1°C) with a 12 hour light/dark cycle, and given free 
access to food and water. All animal studies were reviewed and approved by the Institutional 
Animal Care and Use Committee of the National Institutes of Natural Sciences, and were 
performed in accordance with the institutional guidelines for animal experiments and were 
consistent with the ethical guidelines of the International Association for the Study of Pain. 
All efforts were made to reduce the number of animals for this study. At the end of the 
experiment, the animals were killed with supplemental administration of urethane (2-4 g/kg, 
i.p.).
2.2 Spinal nerve ligation model
Rats aged 5 weeks were used for the spinal nerve ligation model. Under sevoflurane 
anesthesia (3-5 %in O2, delivered by mask) the right L5 and L6 spinal nerves were isolated 
and ligated tightly with 6-0 silk suture, according to the method of Chung [39]. One week 
after the surgery, the withdrawal threshold of the ipsilateral hind paw was assessed with von 
Frey filaments. Animals whose withdrawal threshold was below 8 g (6 weeks old) were used 
for in vivo patch-clamp recordings.
2.3 Behavioral tests
Behavioral testing was carried out in a quiet room away from the colony room in daylight 
and at standard temperature (24 ± 1°C). Thirteen rats aged 6 weeks were included in this 
protocol. The rats were allowed to acclimatise to the test location for ~1 hour before the 
experiment. Rats were put onto a perforated metal platform, and mechanical stimuli were 
delivered to the plantar surface of the hind paw using the Dynamic Plantar Aesthesiometer 
(37450, Ugo Basile, Comerio, Italy) positioned beneath the platform. The equipment raises a 
straight metal filament of diameter of 0.5 mm until it touches the plantar surface of the 
hindpaw and exerts an increasing upwards force (from 1 to 50 g over 20 s) until the paw is 
withdrawn or the preset cut-off is reached (50 g). Dexmedetomidine was administered 
intraperitoneally sequentially from low to high dose in the same rat. Twenty minutes after 
the administration of each dose, the mechanical withdrawal threshold was measured for the 
right paw from the average of five Aesthesiometer trials.
Six rats aged 6 weeks were used for sedation assessment. The observation chambers for 
sedation assessment were 20×20×14cm clear plastic cage with mesh floor. The rats were 
habituated to the chamber for ~1 hour before the experiment. All rats were administered 
0.01, 0.1, 1, 10 and 30 μg/kg of dexmedetomidine intraperitoneally in a sequential manner. 
The sedation assessments were performed 20 minutes after each drug administration. We 
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adopted the sedation rating scale of Chuck et al. [14]. The ratings were as follows: 5-awake, 
active: engaged in locomotion, rearing, head movements or grooming; 4-awake, inactive: 
eyes fully open, head up, little to no locomotion, rearing or grooming, normal posture; 3-
mild sedation: eyes partly closed, head somewhat down, impaired locomotion including 
abnormal posture, use only some limbs, dragging and stumbling; 2-moderate sedation: head 
mostly or completely down, eyes partly closed, flattened posture, no spontaneous 
movement; 1-heavy sedation: eyes mostly closed, loss of righting reflex; 0-asleep: eyes fully 
closed, body relaxed, asleep.
2.4 In vivo patch-clamp recording from SG neurons
The methods used for the in vivo patch-clamp recording from the SG were similar to those 
described previously [19; 21; 58]. Briefly, the rats (n = 66) were anesthetized with urethane 
(1.2-1.5 g/kg, i.p.). Thoracolumbar laminectomy was performed at the level of T12 to L2 to 
expose the lumbar enlargement of the spinal cord. In the case of spinalized rats (3 rats), an 
additional laminectomy was made at the cervical level to allow right-sided cord hemisection 
to interrupt descending inhibitory pathways ipsilateral to the recording site. The rat was 
placed in a stereotaxic apparatus (Model ST-7, Narishige, Tokyo, Japan). After the dura 
mater was opened, the pia-arachnoid membrane was cut to make a window to allow the 
patch electrode to enter into the SG. The surface of the spinal cord was irrigated with 95 % 
O2 - 5 % CO2 equilibrated Krebs solution (in mM: 117 NaCl, 3.6 KCl, 2.5 CaCl2, 1.2 
MgCl2, 1.2 NaH2PO4, 11 glucose, and 25 NaHCO3) at a flow rate of 10-15 ml/min at 38 ± 1 
°C. Patch electrodes were fabricated from thin-walled borosilicate glass capillaries using a 
puller (p-97, Sutter Instrument, Novato, CA), and had resistances of 8-15 MΩ when filled 
with either of potassium-based (in mM: 135 K-gluconate, 5 KCl, 0.5 CaCl2, 2 MgCl2, 5 
EGTA, 5 Mg-ATP, 5 HEPES, pH 7.2 adjusted with KOH) or cesium-based (in mM: 110 
Cs2SO4, 5 tetraethylammonium, 0.5 CaCl2, 2 MgCl2, 5 EGTA, 5 Mg-ATP, 5 HEPES, pH 
7.2 adjusted with CsOH) intracellular solutions. The potassium- and cesium- solutions were 
used for recordings of outward currents and excitatory postsynaptic currents (EPSCs) at a 
holding potential of −70 mV and inhibitory postsynaptic currents (IPSCs) at 0 mV, 
respectively.
The patch electrode was advanced into the spinal cord using a micromanipulator (Model 
MHW-4, Narishige). Blind whole-cell recordings [67] were obtained from SG neurons at a 
depth of 30-200 μm from the surface [22]. The recorded currents were amplified (Axopatch 
200B, Molecular Devices, Sunnyvale, CA) and digitized (Digidata 1321A, Molecular 
Devices) for storage/analysis on a personal computer using a data acquisition program 
(Clampex version 10.3, Molecular Devices). The frequencies and amplitudes of EPSCs/
IPSCs were analyzed with MiniAnalysis software (Synaptosoft, Fort Lee, NJ). The total area 
of IPSCs over a 10 second period (before and in the presence of α2-agonist) was measured 
with Clampfit software (version 10.3, Molecular Devices) reflecting the ongoing synaptic 
charge transfer (pC).
2.5 Extracellular recording from the LC
Eight rats aged 5-8 weeks were included in this protocol. Conventional extracellular and in 
vivo cell-attached patch-clamp recordings were obtained from LC neurons as described 
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previously [51; 59]. Under urethane anesthesia (1.2-1.5 g/kg, i.p.), rats were mechanically 
ventilated after tracheostomy and bilateral thoracotomy was performed to reduce the 
respiratory movement. The head was fixed in a stereotaxic apparatus (Model SR-5R, 
Narishige). The floor of the fourth ventricle was exposed through a posterior occipital 
craniotomy using gentle suction aspiration to remove the central portion of the cerebellum. 
The surface of the exposed brainstem was irrigated with Krebs solution equilibrated with 95 
% O2 -5 % CO2 at 38 ± 0.5°C at a flow rate of 5-10 ml/min. A tungsten electrode 
(impedance, 1 MΩ, A-M systems, Sequim, WA) electrode was placed into the LC and action 
potentials in LC neurons were extracellularly recorded with an AC differential amplifier 
(DAM 80, World Precision Instruments, Sarasota, FL). Firing rate of LC neurons was 
analyzed with Offline Sorter software (version 3, Plexon, Dallas, TX). In some experiments 
cell-attached patch-clamp recordings were made from LC neurons allowing action potential 
discharge to be monitored [59]. LC neurons were identified on the basis of their 
characteristic spontaneous firing and responses elicited by pinch stimulation applied to the 
contralateral hind limb [59]. The spontaneous firing rate of the LC neurons in the present 
study was higher than that (2-3 Hz) reported previously [50]. This is probably due to our 
experimental conditions for example the laminectomy and cerebellectomy may tend to 
increase the firing frequency. The value is similar to that of LC neurons reported by in vivo 
patch-clamp recordings in a similar preparation [59].
2.6 Application of drugs
Dexmedetomidine diluted in saline was intraperitoneally injected 20 min before behavioral 
tests, and administered via a left femoral vein catheter during in vivo patch-clamp and 
extracellular recordings. For spinal or LC application drugs were diluted in Krebs solution 
and superfused onto the surface of the brainstem/cord. We arbitrarily defined neurons as 
being sensitive to a particular drug when the frequency, amplitude or area of the synaptic 
responses was altered by more than 20 % of control. The actions of systemic 
dexmedetomidine on IPSCs were examined in SG neurons of rats aged 5-9 weeks. We tested 
for an effect of age on the action of dexmedetomidine by comparing results from rats of 5-6 
weeks with those aged 7-9 weeks and found no difference between the groups. The drugs 
used were dexmedetomidine (Waterstone Technology, Carmel, IN), L-(−)- norepinephrine 
(+)- bitartrate salt monohydrate, clonidine, tetrodotoxin, prazosin and yohimbine (all from 
Sigma, St. Louis, MO).
2.7 Statistical analysis
All numerical data are shown as mean ± SEM. Statistical significance was determined as p < 
0.05 using the paired Student’s t-test, one-way ANOVA with Dunnett’s post hoc test (for 
withdrawal threshold data), the Kruskal-Wallis test followed by the Stell-Dwass test (for 
sedative assessment data) or Kolmogorov-Smirnov test (cumulative distributions of IPSCs).
3. Results
3.1 Analgesic effects of systemic dexmedetomidine on mechanical nociception
We undertook a behavioral analysis to find the systemic dose range over which 
dexmedetomidine has analgesic effects. We used a dynamic aesthesiometer (Ugo Basile, 
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Italy) to evaluate the effect of dexmedetomidine (ascending doses 0.01-10 μg/kg) on 
mechanical withdrawal threshold. The mechanical baseline withdrawal threshold was 18.5 ± 
2.0 g (n = 13). Dexmedetomidine dose-dependently increased the mechanical withdrawal 
thresholds at doses from 1 μg/kg (27.9 ± 2.1 g, p < 0.01; Fig. 1A). In contrast intraperitoneal 
injection of saline did not change the threshold (control, 20.6 ± 0.8 g; saline, 21.6 ± 0.9 g; n 
= 4; p > 0.05). Dexmedetomidine (1-10 μg/kg) had demonstrable analgesic actions on 
mechanical noxious withdrawal response at doses well below the previously reported 
sedative range [10; 16; 54].
3.2 Sedative effects of systemic dexmedetomidine
We performed a sedation assessment across a range of systemic dexmedetomidine doses. 
The sedative rating score (see section 2.4) before the administration of dexmedetomidine 
was 5 in all rats (n = 6). Intraperitoneal dexmedetomidine (ascending doses 0.01-30 μg/kg) 
dose-dependently decreased the sedation score showing statistical significance at doses from 
1 μg/kg (Fig. 1B). The median sedation scores were 5 at 0.01 and 0.1 μg/kg – awake and 
active; 4 at 1 μg/kg– awake but inactive (p < 0.05); 3.5 at 10 μg/kg - awake but inactive to 
mild sedation (p < 0.01) and 2 at 30 μg/kg moderate to heavy sedation (p < 0.01). Thus a 
dose of 30 μg/kg of systemic dexmedetomidine was needed to produce moderate to heavy 
sedation - equivalent to clinical sedative levels. These results were similar to those reported 
for the effect of dexmedetomidine on EEG by Bol et al.[10].
3.3 Cellular mechanism of action of systemic dexmedetomidine on SG neurons
Ishii et al. showed that bath application of dexmedetomidine activated potassium 
conductances (EC50 of 0.62 μM) to directly inhibit SG neurons in acute spinal cord slices 
[31]. We therefore tested whether low dose systemic dexmedetomidine (1-10 μg/kg) elicited 
outward currents in SG neurons voltage clamped (Vh −70 mV) in whole cell patch clamp 
configuration in vivo using naive and Chung model rats. All neurons studied had membrane 
potentials more negative than −50 mV. The average membrane potential and the input 
membrane resistance were −62 ± 1.2 mV (n = 53) and 384.8 ± 28.3 MΩ (n = 53), 
respectively for neurons recorded with the potassium-based intracellular solution. 
Administration of low dose systemic dexmedetomidine did not induce any significant 
persistent outward currents in vivo (as would be expected to follow post-synaptic α2-
adrenoceptor activation, none detectable at 1 μg/kg, n = 7; 7.0 ± 2.6 pA at 10 μg/kg, n = 7). 
However it was noted that higher doses of systemic dexmedetomidine (>30μg/kg) were 
indeed capable of inducing long lasting outward currents, 23.0 ± 6.2 pA (n = 3), (Fig. 2A, 
3C). In Chung model rats, administration of dexmedetomidine (1 μg/kg) did not induce 
detectable outward currents in any neuron tested (n = 7).
Given the known inhibition of excitatory synaptic transmission by α2-agonists [37], we 
tested for an effect of systemic dexmedetomidine on spontaneous EPSCs in SG neurons. 
Dexmedetomidine (1-30 μg/kg) did not change the frequency (control, 23.3 ± 5.0 Hz versus 
Dex., 23.2 ± 5.0 Hz; p > 0.05, n = 7) or amplitude (control, 15.5 ± 3.1 pA versus Dex., 14.8 
± 2.8 pA; p > 0.05, n = 7) of spontaneous EPSCs. In the presence of tetrodotoxin (TTX), 
dexmedetomidine (1 μg/kg) did not change the frequency (control 6.0 ± 2.7 Hz versus + 
Funai et al. Page 6
Pain. Author manuscript; available in PMC 2014 November 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Dex., 5.9 ± 2.7 Hz; p > 0.05, n = 6) or amplitude (control, 14.2 ± 1.9 Hz versus + Dex., 14.0 
± 1.9 Hz; p > 0.05, n = 6) of miniature EPSCs (Fig. 2B).
Although there was no change in spontaneous and miniature EPSCs, we noted a clear and 
dramatic change in inhibitory synaptic transmission to SG neurons. At a holding potential of 
0 mV, all SG neurons tested exhibited spontaneous IPSCs. There was a resting tone of 
inhibition with average frequency 48.5 ± 3.5 Hz (n = 69) and amplitude 30.9 ± 1.9 pA (n = 
69). These values were similar to those reported in our previous in vivo patch clamp study 
[36]. Dexmedetomidine elicited a barrage of spontaneous IPSCs at doses as low as 0.1 μg/kg 
(shown in Fig. 3A). The enhancement of IPSCs by dexmedetomidine was detected in most 
SG neurons tested (19 of 21; Fig. 3A, B, C). Dexmedetomidine increased the inhibitory 
synaptic charge transfer (measured over a 10 second period) by 121 ± 9 % (n = 4) at 0.01 
μg/kg; 134 ± 10 % (n = 9) at 0.1 μg/kg; 138 ± 5 % (n = 13) at 1 μg/kg and by 148 ± 12 % (n 
= 4) at 10 μg/kg compared to controls (316.6 ± 38.4 pC, n = 19) (Fig. 3C). 
Dexmedetomidine shifted the cumulative event distributions of spontaneous IPSCs to 
shorten the inter-event interval and increase their amplitude (Fig. 3D). Systemic 
administration of another α2-agonist clonidine (40 μg/kg) produced a similar effect with 
increased spontaneous IPSCs (Fig. 3A, right).
3.4 Site of action of low dose dexmedetomidine on IPSCs
We next examined whether the enhancement of IPSCs by dexmedetomidine is mediated by 
a direct action at a spinal level. Dexmedetomidine (0.1-10 μM) applied by superfusion to the 
dorsal surface of the spinal cord [21] did not affect the spontaneous IPSCs (synaptic charge, 
104.8 ± 2.4 % of control, n = 6, p > 0.05, at 0.1 μM; 97.5 ± 2.6 % of control, n = 7, p > 0.05, 
at 1 μM; 96.3 ± 4.9 % of control, n = 4, p > 0.05, at 10 μM) (Fig. 4A, C). In spinalised rats 
(cord hemisected ipsilaterally at cervical level) systemic dexmedetomidine (1 μg/kg) did not 
alter the spontaneous IPSCs (synaptic charge, 96.1 ± 9.4 %, n = 6, p > 0.05; Fig. 4B, C). In 
contrast, the direct application of noradrenaline (50 μM) to the surface of the spinal cord in 
spinalized rats provoked a striking barrage of IPSCs (Fig. 4B). These results suggest that 
low dose systemic dexmedetomidine facilitates IPSCs in SG neurons at a supraspinal level 
via a descending modulatory system.
3.5 Systemic dexmedetomidine engages the descending noradrenergic system to facilitate 
spontaneous IPSCs
Several previous in vitro patch-clamp studies have shown noradrenaline to facilitate 
spontaneous IPSCs in SG neurons in spinal cord slices – an action mediated through 
excitatory α1-adrenoceptors on inhibitory interneurons [5; 6; 23; 25]. On this basis we 
hypothesized that systemic dexmedetomidine may be acting via the descending 
noradrenergic system by disinhibiting LC neurons. Direct superfusion of noradrenaline (50 
μM) to the surface of the spinal cord increased spontaneous IPSCs in 40 out of 48 SG 
neurons tested (Fig. 5A.; synaptic charge transfer increased to 219.8 ± 19.2 % of control). In 
8 of 9 noradrenaline-sensitive cells, systemic dexmedetomidine (1 μg/kg) also enhanced 
spontaneous IPSCs (synaptic charge transfer increased to 157.2 ± 8.0 % of control). In each 
recorded neuron there was a strong correlation between the degree of IPSC facilitation seen 
with spinal noradrenaline and with systemic dexmedetomidine (n = 8, R2 = 0.96; Fig. 5B). 
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Also consistent with this hypothesis was the observation that prazosin (an α1-antagonist, 10 
μM) applied to the spinal cord blocked the facilitatory action of spinal Noradrenaline on 
spontaneous IPSCs (n = 4; Fig. 5A). Similarly the systemic dexmedetomidine facilitation of 
IPSCs was significantly suppressed by concurrent spinal application of prazosin (Dex., 
323.3 ± 85.4 pC versus Dex. + prazosin, 226.3 ± 50.4 pC, n = 4, p < 0.05) (Fig. 5C). 
Spontaneous IPSCs were weakly but not significantly decreased by spinal superfusion of 
prazosin (10 μM) (synaptic charge, 90.9 ± 6.1 % of control, n = 6, p > 0.05). On the other 
hand, the facilitatory action of systemic dexmedetomidine (1 μg/kg) on spontaneous IPSCs 
was not antagonized by spinal superfusion of yohimbine (4 μM), an α2 antagonist (Fig. 5C, 
synaptic charge increased by Dex to 142.4 ± 9.9 % of control, n = 4, p = 0.06). The 
spontaneous IPSC were not affected by spinal application of yohimbine (synaptic charge, 
102.5 ± 13.5 % of control, n = 4, p > 0.05).
These results suggest that the facilitatory action of systemic dexmedetomidine on 
spontaneous IPSCs may involve the descending noradrenergic system and spinal α1 
adrenoceptors.
3.6 The effect of systemically administered dexmedetomidine on LC activity
We next directly assessed whether systemic or locally applied dexmedetomidine could alter 
the excitability of LC neurons in vivo. Stable extracellular or cell-attached patch clamp 
recordings were obtained from a total of 21 LC neurons. These LC recordings showed the 
characteristic biphasic response to pinch stimulation applied to the contralateral hind limb 
(Fig. 6A) [59]. Their average spontaneous firing rates were 8.0 ± 3.1 Hz (n = 21).
During an ascending systemic dexmedetomidine dose protocol we observed that 5 out of the 
7 LC neurons showed an increase (more than 20 % of control) in their firing frequency at 
low doses (139 ± 4 % (n = 5) at 0.01 μg/kg, 155 ± 35 % (n = 5) at 0.1 μg/kg, 200 ± 17 % (n 
= 5) at 1 μg/kg) which was reversed (and in some cases inhibited) at higher doses (78 ± 39 
% of controls, n = 5, Fig. 6B, C; 10 - 30 μg/kg). These results indicate that systemic 
dexmedetomidine at lower doses activates LC neurons.
Next we applied dexmedetomidine at a concentrations of 1 nM onto the dorsal surface of the 
brain stem during LC recording. As shown in Fig. 6D, 4 out of 12 LC neurons showed a 
decrease (more than −20 % of control) in their firing rate, however 5 out of the LC neurons 
tested showed an increase (more than 20 % of control) in their firing rates, at 1 nM (150.9 ± 
6.9 %). At 1 μM, dexmedetomidine inhibited the firing frequency in most (5 out of 6) LC 
neurons tested. These results suggest that dexmedetomidine at lower doses can activate 
some LC neurons.
4. Discussion
In this study, we have examined the antinociceptive action of systemic dexmedetomidine, 
the α2-adrenoceptor agonist, at a spinal level in vivo. We show that inhibitory synaptic 
transmission within the substantia gelatinosa was dramatically enhanced by low-dose 
dexmedetomidine. This action was mediated through a supraspinal mechanism involving the 
descending noradrenergic system at doses of dexmedetomidine that produce minimal 
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sedation (see Fig. 7). Systemic administration of dexmedetomidine at low doses (0.01-10 
μg/kg) activates the LC – a source of the descending noradrenergic projection. This 
activation of the descending noradrenergic pathway enhances spinal inhibitory transmission 
via α1-adrenoceptors not α2-adrenoceptors. Conversely, higher doses of dexmedetomidine 
(more than 10 μg/kg) strongly inhibit LC neurons (perhaps also producing the stronger 
sedative action) and simultaneously induces outward currents in spinal SG neurons via a 
direct postsynaptic α2-activation which probably produces additional analgesic effects (see 
Fig. 7B).
We show that dexmedetomidine has analgesic actions on the withdrawal response to 
mechanical noxious stimuli (1-10 μg/kg). This compares to studies that have examined its 
action on thermal withdrawal latencies where it is effective at doses of 5-20 μg/kg [3; 18; 
70]. Systemic dexmedetomidine produces a loss of righting reflex with an ED50 of ~16 
μg/kg for intravenous bolus administration [54], at doses of >100 μg/kg following 
intraperitoneal administration [16] and sedative action on electroencephalogram at doses 
around 10 μg/kg [10] and a decrease in spontaneous locomotive activity at doses of >30 
μg/kg [56]. Our sedative assessment showed that dexmedetomidine has detectable sedative 
actions at doses of 10 μg/kg and minimal sedation was detected at a dose of 1 μg/kg, but that 
moderate to heavy sedation was only seen at doses of 30 μg/kg. This suggests that there may 
be a dissociation between the dose range over which the mechanical analgesia and the 
clinically relevant sedative effects can be elicited by systemic dexmedetomidine. Given that 
mechanical analgesia was observed over lower dose range than thermal analgesia under light 
sedation [3; 18; 70], it raises the possibility that it may be mediated through a different 
cellular/molecular mechanism from those previously documented.
Based on previous in vitro studies, we hypothesized that low-dose dexmedetomidine (<10 
μg/kg) would act either to directly inhibit SG neurons by activation of a potassium 
conductance [25; 31; 49; 58] or by presynaptic inhibition of excitatory transmission [37; 53; 
58]. However, despite searching specifically for these actions, we only found outward 
currents at high doses (≥30 μg/kg) and never saw any effect on spontaneous excitatory 
synaptic transmission. A previous study demonstrated that dexmedetomidine has direct 
spinal effects in neuropathic pain models at intrathecal doses which are ineffective in normal 
rats [40]. However, we found dexmedetomidine (1 μg/kg) did not induce outward currents in 
SG neurons in allodynic rats. Previous behavioral and in vivo studies showed that 
intrathecally administered dexmedetomidine has an antinociceptive action and produced a 
decrease in spinal neural activity via α2-adrenoceptors [34; 60; 69]. Such direct spinal 
actions to induce outward currents [31] was only seen at high doses in our study but would 
be expected to produce strong analgesic actions (see also Fig. 7).
Our observation of a lack of effect of dexmedetomidine on spontaneous EPSCs is consistent 
with previous in vitro studies showing that noradrenaline had no effect on spontaneous 
EPSCs recorded in SG neurons [31; 37] but was able to suppress primary afferent evoked 
EPSCs. To accurately elucidate the presynaptic effect of dexmedetomidine would require 
electrophysiological experiments to assess paired-pulse ratio and the coefficient of variation 
of evoked EPSCs using spinal cord slice. However, these experiments cannot currently be 
performed in our preparation in vivo so we aimed to test for a presynaptic effect of systemic 
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dexmedetomidine by recording miniature EPSCs in the presence of TTX. Systemic 
dexmedetomidine had no effect on miniature EPSC frequency or amplitude implying that it 
is not acting presynaptically to modulate excitatory transmission. Taken together these 
results suggested that systemic dexmedetomidine at low doses produces antinociception by a 
novel mechanism.
Counter to our expectations, we found low doses of systemic dexmedetomidine enhanced 
spontaneous IPSCs in most SG neurons (~90 %). The enhancement of spinal IPSCs by 
systemic dexmedetomidine was lost in spinalized animals and, importantly, was not 
mimicked by direct spinal application of dexmedetomidine (0.1 – 10 μM). These findings 
suggested that this dexmedetomidine-induced enhancement of spinal IPSCs may be 
dependent upon a descending pathway from the pons [28; 32; 50]. A similar IPSC 
facilitation by noradrenaline has been shown to be present in most (~90 %) SG neurons in 
spinal cord slices in vitro [5; 6] mediated by α1-adrenoceptors. It has further been shown 
that α1-adrenoceptors are expressed in the superficial dorsal horn [27; 62] and that 
noradrenaline acts to excite spinal GABAergic neurons via α1-adrenoceptors [23]. We 
demonstrated this effect in 83% of SG neurons tested in vivo with direct spinal superfusion 
of noradrenaline. Almost all of the SG neurons that responded in this way to noradrenaline 
also showed facilitation of IPSCs by systemic dexmedetomidine. Furthermore this systemic 
action of dexmedetomidine on IPSCs was blocked by spinal application of the α1-
adrenoceptor antagonist prazosin, but not by the α2-adrenoceptor antagonist yohimbine.
As we have discussed already spinal noradrenaline can exert antinociceptive actions by 
several mechanisms; facilitation of inhibitory synaptic responses via α1 adrenoceptors, 
presynaptic inhibition of excitatory synaptic responses and hyperpolarization of SG via α2-
adrenoceptors [50; 58]. Our in vivo patch clamp recordings indicate that the facilitation of 
inhibitory synaptic responses occurs to alter nociceptive transmission before the other direct 
spinally mediated α2-adrenoceptor actions. However the reason for this sensitivity/
specificity and apparent dose threshold difference is still not known, we hope to perform 
more experiments to explore this interesting phenomenon.
The serotonergic pathways form another well-characterized descending monoaminergic 
projection to the spinal dorsal horn from the brain stem, [45; 65]. Previous patch-clamp 
recordings from adult spinal cord slices showed that bath-application of serotonin also 
facilitated inhibitory synaptic responses in SG neurons, although this serotonin-induced 
facilitation of IPSCs was found in a lower proportion (~50 %) of recordings [1; 64]. This 
suggests that both noradrenergic and serotoninergic descending control systems may act 
through a common mechanism to regulate the tonic level of inhibition impinging upon the 
SG. The spinal processing of nociceptive signals is known to be held under tonic regulation 
by GABA/glycinergic IPSCs [57] and that the loss of such inhibition is found in chronic 
pain models [46]. We speculate that the regulation of inhibitory GABA/glycinergic tone 
may be one of the principal means by which descending monoaminergic systems regulate 
nociceptive transmission in the SG.
Although we show that low-dose systemic dexmedetomidine can increase the firing rate of 
LC neurons in vivo, as can low concentrations of dexmedetomidine applied to the dorsal 
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pons over the LC, this is somewhat paradoxical as it has been reported that α2-agonists 
inhibit LC neurons to exert sedative actions [2; 12; 15; 33]. In line with this finding, we 
noted that high doses of systemic dexmedetomidine inhibited LC activity. Interestingly a 
previous behavioral study also showed that injection of dexmedetomidine into the LC 
produced antinociception by activating a descending noradrenergic inhibitory pathway [26] 
but these authors suggested that this might be mediated indirectly via the A5 noradrenergic 
cell group. On the basis of our findings we propose that this analgesic effect may be caused 
by a disinhibition of the LC by low dose dexmedetomidine leading to an increase in 
noradrenaline release at a spinal level. This may be via a selective presynaptic disinhibition 
of the LC (which is known to receive tonic inhibition). It is also worth noting that most α2-
agonists have affinity for imidazoline receptors [29] which are highly expressed in the 
Nucleus Paragigantocellullaris (PGi) in the ventral medulla. The LC is known to receive 
excitatory afferents from the PGi [17], and Pineda et al. have demonstrated that systemically 
administered high dose clonidine can paradoxically increase LC firing rate via an activation 
of imidazoline receptors. Further experiments will be needed to elucidate how LC neurons 
are excited by low doses of dexmedetomidine.
In conclusion, we have revealed a novel antinociceptive mechanism for systemic α2-
adrenoceptor agonists at low doses via the facilitation of inhibitory synaptic transmission in 
the spinal dorsal horn. This is mediated by an activation of the descending noradrenergic 
inhibitory system originating from the LC in the pons which is acting to modulate inhibitory 
tone in the superficial dorsal horn of the spinal cord. This occurs at doses that are below the 
normal sedative range and by targeting this mechanism it may be possible to usefully 
produce analgesia with only minimal sedation, potentially extending the therapeutic utility 
of α2-agonists as analgesics. Further this potentiation of inhibitory synaptic transmission 
may also in part account for the known synergy between anesthetic agents that themselves 
potentiate inhibitory synaptic transmission (via a GABAA receptor mediated mechanism) 
and dexmedetomidine.
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Figure 1. Dose-dependent anti-nociceptive and sedative action of systemic dexmedetomidine
A) Paw withdrawal thresholds to mechanical stimuli were measured in conscious animals 
using the Dynamic Plantar Aesthesiometer 20 min after intraperitoneal administration of 
dexmedetomidine (DEX, 0.01 to 10 μg/kg, n = 13). Dexmedetomidine significantly 
increased the withdrawal threshold at doses of 1 μg/kg (*p < 0.05) and 10 μg/kg (**p < 
0.01) compared control prior to drug administration (n = 13, one-way ANOVA and 
Dunnett’s post hoc test).
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B) The sedation rating scores were assessed 20 minutes after intraperitoneal 
dexmedetomidine (DEX, 0.01 to 10 μg/kg, n = 6). Median scores were significantly 
decreased at 1 μg/kg (*p < 0.05) and 10 μg/kg (**p < 0.01) compared with pre-
administration control (Kruskal-Wallis test followed by the Stell-Dwass test) although most 
of the animals were considered to be still awake or only mildly sedated in this dose range. 
Only those animals receiving 30 μg/kg showed evidence of moderate to heavy sedation 
which was a significantly greater degree of sedation than that produced by either 1 or 10 
μg/kg (p < 0.05).
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Figure 2. Effect of systemic dexmedetomidine on SG neuron excitability
A) To look for α2-adrenoceptor mediated activation of potassium currents, we voltage 
clamped SG neurons (holding potential of −70mV with a potassium-based intracellular 
solution). The application of low doses of dexmedetomidine (1 μg/kg) did not elicit any 
detectable outward currents (left trace). In contrast, much higher doses of dexmedetomidine 
(30-75 μg/kg) were required to produce any sign of an outward current (right trace).
B) In the presence of tetrodotoxin (TTX), systemic administration of dexmedetomidine (1 
μg/kg) did not enhance miniature EPSCs. The traces below are shown on an expanded time 
base to demonstrate the resolution of individual miniature EPSCs. The cumulative 
probability plots for the inter-event interval and amplitude of miniature EPSCs (from the 
trace in B), showing dexmedetomidine has no effect on either the frequency or amplitude (p 
> 0.05, Kolmogorov-Smirnov test).
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Figure 3. Systemic dexmedetomidine dose-dependently enhances spontaneous IPSCs in the SG
A) Systemic dexmedetomidine (left trace, 0.1 μg/kg) and clonidine (right trace, 40 μg/kg) 
elicited barrages of spontaneous IPSCs (holding potential of 0 mV with a cesium-based 
based solution). The traces below are shown on an expanded time base to demonstrate the 
individual IPSCs.
B) Dexmedetomidine dose-dependently elicits barrages of spontaneous IPSCs.
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C) Summary plot showing the enhancement of IPSCs (open circles) at dexmedetomidine 
doses (<10 μg/kg) that are lower than those required to induce outward currents (closed 
circles).
D) The cumulative probability plots for the inter-event interval and amplitude of 
spontaneous IPSCs (from the left trace in A). Dexmedetomidine at a dose of 0.1 μg/kg 
significantly increased the frequency (p < 0.01) and amplitude (p < 0.01) of spontaneous 
IPSCs (Kolmogorov-Smirnov test).
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Figure 4. Dexmedetomidine does not enhance IPSCs by a direct spinal action
A) Spinal superfusion of dexmedetomidine (10 μM) had no effect on spontaneous IPSCs. In 
the same neuron, subsequent systemic application of dexmedetomidine (1 μg/kg) enhanced 
IPSCs.
B) Recordings from SG neurons in rats spinalized at the cervical level showed that systemic 
application of dexmedetomidine (1 μg/kg) no longer changed IPSC frequency or amplitude. 
However, spinal application of noradrenaline (NA, 50 μM) was able to dramatically 
facilitate IPSCs in the same neuron.
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C) Summary showing effects of direct spinal superfusion of dexmedetomidine (0.1 – 10 
μM), and systemic dexmedetomidine application in spinalized rats on normalized synaptic 
charge of spontaneous IPSCs.
Funai et al. Page 22
Pain. Author manuscript; available in PMC 2014 November 20.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 5. Spinal noradrenaline and systemic dexmedetomidine facilitate IPSCs in the same SG 
neurons
A) In this neuron the facilitation of IPSCs by local superfusion of noradrenaline (NA, 50 
μM, shown in upper trace) and systemic dexmedetomidine is blocked by spinal application 
of the α1-adrenoceptor antagonist prazosin (10 μM, lower trace). Data in A were obtained 
from the same neurons shown in Fig. 4A.
B) There was a strong correlation between the facilitatory actions of spinal noradrenaline 
and systemic dexmedetomidine on spontaneous IPSCs evoked in the same SG neurons 
(linear regression R2 = 0.96).
C) Summary chart showing the facilitatory action of systemic dexmedetomidine on 
spontaneous IPSCs which is blocked in the presence of spinal prazosin (an α1 antagonist, 10 
μM) but not by yohimbine (an α2 antagonist, 4 μM).
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Figure 6. Activation of LC neurons by low-dose systemic dexmedetomidine
A) The characteristic biphasic response with excitation followed by inhibition of LC neuron 
firing by cutaneous pinch stimulation applied to the contralateral hind paw (cell-attached 
patch recording).
B) Extracellular recording showing several discriminated spontaneous LC units (right 
panels). For each cell the firing rate was increased by low dose systemic dexmedetomidine 
(1 μg/kg). However, higher doses of dexmedetomidine (30 μg/kg) strongly inhibited the 
firing of the same neurons.
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C) Normalized firing rates of LC neurons after systemic dexmedetomidine (1-30 μg/kg). The 
firing rate was increased in 5 of 7 LC neurons at 1 μg/kg.
D) Normalized LC firing rates after superfusion of Dexmedetomidine over the floor of the 
4th ventricle. Firing rates were increased in a substantial proportion of the cells (5/11) at 
1nM Dexmedetomidine but the majority of the cells were inhibited by the 1uM dose. 
Dashed lines in C and D show 20% increase or decrease in normalized firing frequency.
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Figure 7. Schematics summarizing the proposed mechanisms of action of systemic 
dexmedetomidine
A) Low dose systemic dexmedetomidine (DEX) facilitates spinal IPSCs by disinhibiting a 
noradrenergic descending pathway. The spinal noradrenaline (NA) acts via pre- and 
postsynaptic α1 adrenoceptors on the GABAergic and glycinergic inhibitory neurons to 
facilitate inhibitory synaptic transmission onto SG neurons. In contrast, high dose 
dexmedetomidine inhibits the LC, perhaps leading to sedation, and also directly activates 
α2-adrenoceptors on the SG neurons to induce outward potassium currents that 
hyperpolarize and inhibit the cells producing analgesia by a different mechanism.
B) Diagram showing the multiple actions of systemically administered dexmedetomidine at 
different doses. The analgesia and the facilitation of spontaneous IPSCs appear with low 
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doses of systemic dexmedetomidine (0.1-1 μg/kg). At these doses dexmedetomidine 
enhanced the activity of LC neurons. Higher doses (10-75 μg/kg) of dexmedetomidine were 
needed to induce outward currents in SG neurons while also directly inhibiting the LC 
perhaps producing the known sedative effect.
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